Literature DB >> 3925775

Prospective pricing system and its effect on the principles and practice of infectious diseases.

M Turck, J Smith.   

Abstract

The health care industry in general and hospitals in particular face an uncertain future as the federal government moved with unusual speed to enact sweeping Medicare legislation. These changing patterns of reimbursement reverse key economic incentives by which hospitals have been driven since the federal program for the elderly began 18 years ago. "Reasonable" cost reimbursement has been replaced by a policy that requires Medicare to establish and fix prices in advance, on a cost-per-case basis, using as a measure 467 categories called "diagnosis-related groups." These changes will present new challenges for the health care industry and will need innovative approaches to meet them. The prospective pricing system attempts to reverse the escalation of health care costs. Under this system, hospitals can realize greater profits only by reducing costs, not by incurring them. The prospective payment system will have profound effects on the practice of infectious diseases, and the potential impact on hospitals, the pharmaceutical industry, physicians, and patients will have to be studied in detail.

Entities:  

Mesh:

Year:  1985        PMID: 3925775     DOI: 10.1016/0002-9343(85)90359-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  The role of infectious disease physicians in hospital clinical microbiology laboratories.

Authors:  J M Matsen
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

2.  Economics and infectious diseases in the academic medical center--the perspective of a chairman of medicine.

Authors:  D Kaye; L I White
Journal:  Bull N Y Acad Med       Date:  1988 Jul-Aug

3.  Actinomycosis of the Appendix Mimicking Cecal Tumor Treated by Single-Port Laparoscopic Approach.

Authors:  In Soo Cho; Sung Uk Bae; Hye Ra Jung; Kyung Sik Park; Woon Kyung Jeong; Seong Kyu Baek
Journal:  Ann Coloproctol       Date:  2020-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.